Investors comparing healthcare technology names often weigh established platforms against smaller, higher-growth options. This look at VEEV and WAY highlights that contrast. Veeva Systems stands out as a leading provider of cloud software for life sciences, while Waystar Holding focuses on payments and revenue-cycle tools for healthcare providers. Both rely on recurring subscription revenue and are incorporating artificial intelligence, yet their sizes, growth trajectories, and recent market behavior set them apart. I also checked relative positioning using Tickeron’s AI Screener to round out the picture.
VEEV (Veeva Systems Inc.) delivers cloud-based software and data solutions for pharmaceutical, biotechnology, and life sciences firms, covering CRM, content management, clinical data, regulatory, and quality processes. It operates at meaningful scale, with a market capitalization near $50 billion and a profitable, cash-generative subscription model.
Over the past several months, VEEV shares have shown clear strength, rising notably over the trailing three-month window and holding well above their 52-week lows. Positive sentiment has been reinforced by ongoing AI product updates, including tools to speed clinical study setup and manage safety reports, along with several analyst target increases. While revenue growth has moderated from a larger base and the company continues migrating CRM customers to the Vault platform, the stock’s relative performance has stayed positive.
WAY (Waystar Holding Corp.) offers cloud software that streamlines healthcare payments and revenue-cycle management for providers, patients, and payers. Based in Lehi, Utah, the company carries a market capitalization of roughly $5.5 billion and maintains high margins with strong cash generation.
Recent weeks have brought more mixed price action for WAY. The firm posted about 21% year-over-year revenue growth, with adjusted EBITDA margins in the mid-40% range, its largest client win to date, and net revenue retention of 108%. Still, the stock pulled back after management provided forward revenue guidance that pointed to a slower near-term pace, citing extended implementation timelines for its AI-driven offerings. This mix of solid underlying demand and tempered growth expectations has left sentiment and relative performance more uneven.
Although both operate in healthcare software, their models and risk profiles differ in important ways. VEEV functions as a broad, dominant platform serving life sciences clients across commercial and R&D areas, supported by deep regulatory knowledge and cross-selling potential. Its size underpins strong profitability and a conservative balance sheet, though the mature base translates to slower percentage growth and a valuation that offers limited margin for error.
WAY, on the other hand, is a smaller, more focused player in revenue-cycle and payment automation. It is expanding revenue more quickly than VEEV and enjoys attractive margins, yet it contends with longer contract ramps, greater dependence on AI adoption for acceleration, and elevated short interest. These differences create distinct trade-offs: VEEV provides stability and established leadership, while WAY presents a higher-growth, higher-beta profile with added near-term guidance uncertainty.
Considering factors such as trend consistency, relative momentum, scale, and market positioning, Tickeron’s AI currently points to VEEV in this matchup. Veeva’s sustained upward price move, solid profitability, and steady product catalysts have aligned with stronger relative performance, whereas Waystar’s softer forward guidance and extended revenue ramps add more near-term variability. This reflects a probabilistic view of current conditions rather than a firm forecast and should be considered alongside individual research and risk tolerance.
In my research process, I frequently review Tickeron’s AI Trading Bots to see how systematic strategies are positioned around individual names. The platform curates a selection of bots across styles, timeframes, and performance metrics, offering a practical way to cross-check manual analysis with automated signals that update with live market data.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
VEEV saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 78 similar instances where the indicator turned negative. In 54 of the 78 cases, the stock moved further down in the following days. The odds of a decline are at 69%.
The Moving Average Convergence Divergence Histogram (MACD) for VEEV turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 31 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
VEEV moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VEEV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +0.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where VEEV advanced for three days, in 179 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
VEEV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 133 of 210 cases where VEEV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. VEEV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.617) is normal, around the industry mean (4.523). VEEV has a moderately high P/E Ratio (48.989) as compared to the industry average of (12.601). Projected Growth (PEG Ratio) (1.248) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (12.739) is also within normal values, averaging (6.105).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VEEV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of industry-specific, cloud-based software solutions for the life sciences industry
Industry ServicestotheHealthIndustry